COAG

Peers: QURE AGIO IRON RARE NVO KROS SNY AAPG BCRX ABCL

| Held by: XBI IWM VTI VXF IWO SCHA VTWO IWN FFSM TMSL

Index	RUT
Market Cap	1.92B
Enterprise Value	1.47B
Income	-
Sales	-
Book/sh	9.73
Cash/sh	9.79
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	72
IPO	May 01, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.23
P/C	4.20
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	35.85
Current Ratio	35.85
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.47
EPS next Q	-0.50
EPS this Y	95.48%
EPS next Y	19.06%
EPS next 5Y	64.54%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-9.22% -

Insider Own	38.27%
Insider Trans	19.93%
Inst Own	60.29%
Inst Trans	46.50%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	21.17%
SMA50	9.00%
SMA200	11.75%
Trades

Shs Outstand	46.71M
Shs Float	28.84M
Short Float	10.96%
Short Ratio	6.89
Short Interest	3.16M
52W High	55.42 -25.77%
52W Low	23.00 78.87%
Volatility	7.33% 7.86%
ATR (14)	2.70
RSI (14)	65.93
Beta	-
Rel Volume	0.51
Avg Volume	458.83K
Volume	218,251

Perf Week	14.21%
Perf Month	32.24%
Perf Quarter	-11.56%
Perf Half Y	62.35%
Perf YTD	52.37%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	61.71
Prev Close	41.45
Price	41.14
Change %	-0.75%

Consensus

Strong Buy

Avg. Price Target

$61.71

Implied Upside

+50.0%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	JJP Morgan	Overweight	$70	+70.2%
Oct 12, 2026	Initiated	RRodman & Renshaw	Buy	$56	+36.1%
Jun 17, 2026	Initiated	HH.C. Wainwright	Buy	$40	-2.8%
May 26, 2026	Initiated	WWedbush	Outperform	$42	+2.1%
May 26, 2026	Initiated	JJefferies	Buy	$39	-5.2%
May 26, 2026	Initiated	GGoldman	Buy	$36	-12.5%
May 26, 2026	Initiated	EEvercore ISI	Outperform	$50	+21.5%

Sep-24-26 04:01PM	Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert (GlobeNewswire)
Sep-17-26 08:00AM	Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding (GlobeNewswire)
Aug-11-26 07:00AM	Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-21-26 08:35AM	Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg)
Jul-14-26 07:45AM	Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress (GlobeNewswire) +9.62%
06:28AM	Loading…
Jul-12-26 06:28AM	Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress (GlobeNewswire)
Jun-26-26 09:00AM	Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress (GlobeNewswire) +16.77%
May-27-26 08:00AM	Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-26 07:00AM	Hemab Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 04:01PM	Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -25.47%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 16 '26	Buy	24.98	61,523	1,536,845	6,444,637	Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 15 '26	Buy	24.89	6,146	152,974	6,383,114	Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 19 '26	Buy	24.97	3,802	94,936	6,375,972	May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 20 '26	Buy	24.94	996	24,840	6,376,968	May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 12 '26	Buy	24.90	6,387	159,036	6,372,170	May 14 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 11 '26	Buy	24.81	39,869	989,226	6,365,783	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 07 '26	Buy	24.46	9,906	242,323	6,324,431	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 08 '26	Buy	24.98	1,483	37,045	6,325,914	May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 04 '26	Buy	18.00	2,675,000	48,150,000	6,149,096	May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 05 '26	Buy	24.63	97,411	2,399,546	6,246,507	May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 06 '26	Buy	24.60	68,018	1,673,399	6,314,525	May 06 07:16 PM

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA.

Ph.D.Dr. Benny Sorensen M.D.

CFO & GMMr. Mads Nikolaj Behrndt-Eriksen M.Sc.

Chief Medical OfficerDr. Catherine Eilleen Madigan M.D.

Ph.D.Dr. Ananthram Sreenivasa Murthy M.Sc.

Chief People & Culture OfficerMs. Karen Weisbach

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Hemab Therapeutics Holdings Inc

Upgrade your Finviz experience